Biotech financing
25WmEet
25WmEet
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Top European venture <strong>financing</strong>, 2015<br />
Company Country Lead product clinical stage Status<br />
Amount<br />
(US$m)<br />
Month<br />
Immunocore* UK Phase II Oncology 313 July<br />
Nabriva Therapeutics Austria Phase II Infectious disease 120 April<br />
Mereo BioPharma* UK Phase III Multiple 117 July<br />
CureVac Germany Phase II Oncology 111 November<br />
Merus Netherlands Phase I Oncology 81 August<br />
ADC Therapeutics Switzerland Phase I Oncology 80 September<br />
Symphogen Denmark Phase II Oncology 75 October<br />
CureVac Germany Phase II Multiple 74 March<br />
CRISPR Therapeutics Switzerland Preclinical Genetic diseases 64 April<br />
ObsEva Switzerland Phase II Women's health 60 November<br />
Kymab UK Preclinical Multiple 50 May<br />
Autolus UK Preclinical Oncology 46 January<br />
Sanifit Spain Phase II Hematology 41 September<br />
PsiOxus Therapeutics UK Phase II Oncology 38 May<br />
GenSight Biologics France Phase III Ophthalmic 36 July<br />
Source: EY, Capital IQ and VentureSource.<br />
*First venture round<br />
Beyond borders 2016 — <strong>Biotech</strong> <strong>financing</strong><br />
23